688136 Kexing Biopharm
- 19.75
- +0.73+3.84%
Kexing Biopharm News
Kexing Biopharm Obtained Clinical Trial Approval for Its Self-developed Class I Innovative Drug--Long-acting Growth Hormone
On the 24th of May, Kexing Biopharm (688136.SH) announced that Shenzhen Kexing Pharmaceutical Co., Ltd., its wholly-owned subsidiary, recently...
Kexing Pharmaceuticals (688136): A Scarce Emerging Market Overseas Platform Turns Losses into Profits in 2024Q1
The quality of operations improved, and 2024Q1 turned losses into profits. The company published the 2023 annual report and the quarterly report for the first quarter of 2024. In 2023, it achieved revenue of 1,259 billion, a year-on-year decrease of 4.32%; achieved net return to mother
Kexing Biopharm's Unit to Trial Growth Deficiency Drug
Kexing Biopharm's (SHA:688136) unit, Shenzhen Kexing Bioproducts, will conduct clinical trials on GB08 injection after obtaining approval from China's National Medical Products Administration, the com
Kexing Pharmaceuticals (688136) Comment: Issuing an Equity Incentive Plan to Ensure the Smooth Implementation of the “Internationalization” Strategy
Incident: Kexon Pharmaceuticals announced the 2024 Restricted Stock Incentive Plan (draft). The number of restricted shares to be granted under this incentive plan accounts for 1.90% of the company's total share capital. A total of 147 people are to be awarded incentives, accounting for the total number of employees of the company
Express News | Kexon Pharmaceuticals: Self-developed Class I innovative drug long-term growth hormone clinical trial application approved
Kexing Pharmaceuticals (688136): The main business performance of recombinant proteins is steady, and the value of the overseas commercialization platform accelerates the realization of value
Key investment points Investment logic: High-quality overseas platform: With more than 20 years of overseas experience, we have achieved full coverage of all emerging market countries with a population of over 100 million and top 30 GDP, and have reached authorized cooperation on 13 overseas projects, and are expected to land at sea one after another
Kexon Pharmaceuticals (688136.SH): Proposed 3.786 million restricted stock incentive plan
Ge Longhui, May 24, 丨 Kexon Pharmaceuticals (688136.SH) announced the 2024 restricted stock incentive plan. The number of restricted shares to be granted under this incentive plan is 3.786 million shares, accounting for 1.90% of the company's total share capital of 19.919.865 million shares when the draft incentive plan was announced. This incentive plan is intended to grant incentives to a total of 147 people. The grant price of restricted shares under this incentive plan is 12 yuan/share.
Express News | Kexon Pharmaceuticals: Subsidiary approved for clinical trial of GB08 injection
Kexing Pharmaceuticals (688136.SH): A total cost of 31.12 million yuan to buy back 0.94% of shares
Gelonghui, May 21丨Kexon Pharmaceuticals (688136.SH) announced that as of the disclosure date of this announcement, the company's share repurchase period has expired, the company's cumulative repurchase amount through centralized bidding transactions has reached the lower limit of the repurchase amount, and the implementation of this share repurchase plan has been completed. The company has repurchased 1,880,572 shares of the company's shares through the Shanghai Stock Exchange trading system, accounting for 0.94% of the company's total share capital. The highest price of the repurchase transaction was 19.95 yuan/share, the lowest price was 14.30 yuan/share, the average repurchase price was 16.55 yuan/share, and the total amount of capital paid
Kexing Biopharm-Anlage Besteht EU-GMP-Zertifizierung Für Paclitaxel Zur Injektion (Albumin Gebunden)
SHENZHEN, China, 10. Mai 2024 /PRNewswire/ -- Am Abend des 5. Mai hat Kexing Biopharm (Aktiencode: 688136) bekanntgegeben, dass das Unternehmen von der norwegischen Arzneimittelbehörde gemäß den Vo
Kexing Biopharm Obtiene La Certificación GMP De La UE Para Paclitaxel Inyectable (Unido a Albúmina)
SHENZHEN, China, 10 de mayo de 2024 /PRNewswire/ -- En la tarde del 5 de mayo, Kexing Biopharm (código bursátil: 688136) anunció que había obtenido un "Certificado de Conformidad GMP de un Fabric
Kexing Biopharm Facility Passes EU GMP Certification for Paclitaxel for Injection (Albumin Bound)
SHENZHEN, China, May 10, 2024 /PRNewswire/ -- On the evening of May 5, Kexing Biopharm (stock code: 688136) announced it had obtained a "Certificate of GMP Compliance of a Manufacturer" granted by th
Kexon Pharmaceuticals (688136): The pace of GMP factory inspections in many countries is in line with expectations, and the EU is more certain that Bai Zi will go overseas
Ping An's view: The EU market space pattern is good, and the company's peak sales volume in the EU is expected to exceed 700 million yuan. According to the company's announcement, by the end of 2023, the 12 products introduced by the company had signed contracts with customers in more than 40 countries and one after another
Kexing Pharmaceuticals (688136) Company Brief Review Report: Domestic business is stable and waiting for breakthroughs in internationalization
Incident: The company released its 2023 annual report. In 2023, it achieved operating income of 1,259 million yuan (-4.32%), net profit to mother of -190 million yuan, and net profit of non-return to mother of -210 million yuan. 202
Express News | Science and Technology Innovation Board Review: The Science and Technology Innovation 50 Index closed down 1.01%, and aerospace concept stocks surged
Ongoing Expansion in Manufacturing, Services Bolsters Chinese Stocks; Kexing Biopharm Up 8%
Chinese stocks resumed trading with gains after a private reading showed that China's service sector and business activity continued to expand in April. The Shanghai Composite Index added 1.2%, or 35.
Express News | Science and Technology Innovation Board Evaluation: The biological products sector is strong and surging, and the semiconductor and lithium battery sectors are rising
Kexing Biopharm Gets GMP Certificate From Norway's Drug Regulator
The Norwegian Medical Products Agency granted a certificate of good manufacturing practice or GMP compliance to Chinese drugmaker Kexing Biopharm (SHA:688136), according to the company's filing on the
Express News | Kexon Pharmaceuticals establishes a biomedical subsidiary in Guangzhou
Kexon Pharmaceuticals: Passed EU GMP certification
Glonghui, May 5 | Kexon Pharmaceuticals announced that it recently received the “Pharmaceutical GMP Certificate” issued by the Norwegian Medicines Agency in accordance with relevant regulations of the European Medicines Agency. The certified product is paclitaxel for injection (albumin binding type) (5 mg/ml). Injectable paclitaxel (albumin binding) is the mainstream first-line medication recommended by the European Society of Medical Oncology guidelines for the treatment of metastatic pancreatic cancer and non-small cell lung cancer. According to the GMP mutual recognition system among EU member states, passing the GMP certification this time indicates that the production line that has been certified has met EU GMP standards, and the company has paclitaxel (albumin binding) products for injection
Analysis
Price Target
No Data
